Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leonard Zemel

Endocrinology, Diabetes & Metabolism Denver, CO Medical Doctor

NPI 1447256045 CMS profile 291914

3464 S Willow St, # 280, Denver, CO 80231

Open in the dashboard

General payments

$18,501

562 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$709,101 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Leonard Zemel of Denver, CO is reported in the CMS Open Payments database as having received $18,501 across 562 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $709,101 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $91 1
2024 General $121 1
2023 General $588 10
2022 General $1,510 85
2021 General $7,528 137
2020 General $5,244 171
2019 General $3,420 157

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leonard Zemel
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Leonard Zemel were reported at $91. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Leonard Zemel Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $3,420 $494 $123–$2,253 $163
2020 $5,244 $335 $85–$1,841 $114
2021 $7,528 $398 $88–$1,981 $132
2022 $1,510 $364 $88–$1,568 $149
2023 $588 $420 $113–$1,614 $160
2024 $121 $440 $121–$1,646 $164
2025 $91 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $4,192 143 payments
  2. Sanofi-Aventis U.S. LLC $3,948 35 payments
  3. Tandem Diabetes Care, Inc. $1,700 6 payments
  4. Mannkind Corporation $1,454 79 payments
  5. AstraZeneca Pharmaceuticals LP $1,337 56 payments
  6. Mylan Specialty L.P. $1,038 1 payment
  7. Lilly USA, LLC $612 35 payments
  8. Abbott Laboratories $468 12 payments
  9. Antares Pharma, Inc. $368 23 payments
  10. Amarin Pharma Inc. $326 14 payments
  11. Other $3,057 158 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,009 547 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,920 6 payments
  3. Consulting Fee $3,528 4 payments
  4. Education $44 5 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $3,337 96 payments
  2. Ozempic $1,579 127 payments
  3. FARXIGA $1,284 55 payments
  4. t-slim insulin pump $1,250 5 payments
  5. AFREZZA Diabetes Medicine $1,086 61 payments
  6. t:slim X2 insulin pump $450 1 payment
  7. AFREZZA Diabetes Medicine $369 18 payments
  8. JARDIANCE Diabetes $307 17 payments
  9. UNITHROID $280 20 payments
  10. JARDIANCE Diabetes $272 16 payments
  11. Other $6,432 306 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

94

Median for Internal Medicine: 777

Drug cost

$29,624

Median for Internal Medicine: $73,373

Branded share of claims

14.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 14 $28,832
Metformin Hcl Generic 20 $337
Levothyroxine Sodium Generic 38 $304
Atorvastatin Calcium Generic 22 $151

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

562 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record